| Identification | More | [Name]
5-Bromo-2'-deoxycytidine | [CAS]
1022-79-3 | [Synonyms]
2'-DEOXY-5-BROMOCYTIDINE
5-BR-DC
5-BROMO-2'-DEOXYCYTIDINE
5-BROMO-2'-DEOXYCYTIDINE MONOHYDRATE
5-BROMODEOXYCYTIDINE
5-bromo-2’-deoxy-cytidin
5-Bromo-2'-deoxy-D-cytidine
5-BROMO-2''-DEOXYCYTIDINE(5-BRDC)
Bromodeoxycytidine
5-BROMO-2''-DEOXYCYTIDINE crystalline
5-BROMO-2''-DEOXYCYTIDINE, HPLC PURIFIED, 98% PURE WITH HPLC UV CHROMATOGRAM
4-Amino-5-bromo-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-(2-deoxy-β-D-ribofuranosyl)-5-bromopyrimidin-2(1H)-one | [EINECS(EC#)]
213-824-2 | [Molecular Formula]
C9H12BrN3O4 | [MDL Number]
MFCD00047496 | [Molecular Weight]
306.11 | [MOL File]
1022-79-3.mol |
| Hazard Information | Back Directory | [Uses]
5-Bromo-2'-deoxycytidine (BrdC) is a brominated derivative of the deoxyribonucleoside 2’-deoxycytidine. It induces DNA cross-linking and the formation of DNA strand breaks when incorporated into a DNA fragment in place of cytosine and exposed to UVB damage. BrdC inhibits cytopathogenicity induced by herpes simplex virus 1 (HSV-1) and HSV-2 in infected primary rabbit kidney (PRK) cells (MICs = 0.2-0.3 μg/ml). It decreases the survival of U-1 melanoma cells and AG1522 non-cancerous cells and induces sensitization of both to radiation. BrdC also sensitizes tumors to radiation and reduces tumor volume in a mouse model of glioma using RT-2 cells infused with an adenovirus expressing HSV thymidine kinase (ADV-TK) after implantation. In vivo, BrdC is converted to 5-bromo-2'-deoxyuridine (BrdU) and has been used to label cardiac progenitor cells (CPCs) in a rat model of myocardial infarction.
|
|
|